Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342752 | 1.00 | ADRB2 (0.41) | ADRB2PDE2ACYP2A6CYP2B6CYP3A4 | |
| SCHEMBL595307 | 1.00 | ADRB2 (0.41) | ADRB2PDE2ACYP2A6CYP2B6CYP3A4 | |
| SCHEMBL6210422 | 0.83 | FOLH1 (0.33) | ADRB2CYP2A6CYP2B6CYP3A4CYP2C19 | |
| SCHEMBL30144069 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL3513409 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL25489183 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL29974411 | 0.78 | CYP2A6 (0.34) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL17000184 | 0.78 | CYP2A6 (0.34) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL7999672 | 0.78 | CYP11B2 (0.35) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL29790356 | 0.78 | CYP2A6 (0.38) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | ADRB2 286/4885PDE2A 850/4885CYP2A6 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.